Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial (2018)
- Authors:
- Autor USP: HEGG, ROBERTO - FM
- Unidade: FM
- DOI: 10.1001/jamaoncol.2018.0060
- Subjects: NEOPLASIAS MAMÁRIAS; ANTINEOPLÁSICOS; RECEPTORES HORMONAIS
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Jama oncology
- ISSN: 2374-2437
- Volume/Número/Paginação/Ano: v. 4, n. 7, p. 977-984, 2018
- Este artigo possui versão em acesso aberto
- URL de acesso aberto
- PDF de acesso aberto
- Versão do Documento: Versão publicada (Published version)
-
Status: Artigo possui acesso gratuito no site do editor (Bronze Open Access) -
ABNT
ROYCE, Melanie e HEGG, Roberto. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, v. 4, n. 7, p. 977-984, 2018Tradução . . Disponível em: https://doi.org/10.1001/jamaoncol.2018.0060. Acesso em: 11 mar. 2026. -
APA
Royce, M., & Hegg, R. (2018). Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial. Jama oncology, 4( 7), 977-984. doi:10.1001/jamaoncol.2018.0060 -
NLM
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2026 mar. 11 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060 -
Vancouver
Royce M, Hegg R. Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial [Internet]. Jama oncology. 2018 ; 4( 7): 977-984.[citado 2026 mar. 11 ] Available from: https://doi.org/10.1001/jamaoncol.2018.0060 - Eficacia, tolerabilidade e aceitabilidade do estradiol transdermico no tratamento dos sintomas da menopausa
- Sindrome do climaterio: conceito, importancia e epidemiologia
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
- Câncer da mama: quadro clínico, diagnóstico e estadiamento
- Mastite puerperal
- Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA)
- Galactorreia: sindrome hiperprolactinemica
- Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
Informações sobre a disponibilidade de versões do artigo em acesso aberto coletadas automaticamente via oaDOI API (Unpaywall).
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
